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Source/Description: Analysis of the published sequence of the
human interleukin 2 receptor ,B (IL- 2R,B) gene revealed a
dinucleotide repeat of the form (GT)n (1). Using the DNA
sequence, polymerase chain reaction (PCR) primers flanking the
repeat were designed to yield an amplified fragment with a




Polymorphism and Frequency: Estimated from 11 unrelated
individuals.
Heterozygosity = 91%
Allele (bp) Frequency Allele (bp) Frequency
163 0.09 155 0.09
161 0.09 153 0.09
159 0.18 151 0.09
157 0.18 149 0.18
Chromosomal Localization: The IL-2Rfl gene was localized to
22qll.2-ql2 by somatic cell hybrid mapping (1).
Mendelian Inheritance: Co-dominant segregation was observed
in four two-generation families.
Other Comments: PCR amplification was performed in a total
volume of 100 AL containing: 100 ng genomic DNA, 250 nM
of each primer, 200 nM of each dNTP, 1.5 mM MgCl2, 50
mM KCl, 10 mM Tris/HCl pH 9.0, 0.01 % gelatin, 0.1 % Triton
X-100, and 1.25 units of Taq polymerase (Promega). Primer
TG-01 was 5' end labeled with oy-32P-dATP. After denaturation
at 94°C for 3 min, amplification was carried out for 30 cycles
with denaturation at 94°C for 20 sec, annealing at 55°C for 20
sec, and elongation at 72°C for 30 sec. PCR products were
resolved on a 6% polyacrylamide gel and visualized by
autoradiography. Fragment sizes were determined by comparison
to an M13 sequencing ladder.
References: 1) Gnarra,J.R., Otani,H., Wang,M.G.,
McBride,O.W., Sharon,M. and Leonard,W.J. (1990) Proc. Natl.
Acad. Sci. USA 87, 3440-3444.
A NlaiV polymorphism within the
human Factor X gene
Anders Wallmarkl, Virgil L.Rose, Coty Ho and
Katherine A.High*
Departments of Medicine and Pathology, and the Center
for Thrombosis and Hemostasis, The University of North
Carolina at Chapel Hill, Chapel Hill, NC 27599-7260, USA
and 'Department of Medicine, Coagulation Disorders,
Malmo General Hospital, Malmo, Sweden
Source/Description: We describe a sequence variant occurring
in exon 7 of the gene encoding blood coagulation Factor X. The
variant is found at residue 817 of the cDNA (numbering system
of Leytus et al. [1]), where either a C or a T may be present.
The polymorphism is silent at the amino acid level, since both
triplets (ACT-'ACC) encode threonine. The latter sequence,
but not the former, forms part of a restriction enzyme recognition
site for the enzyme NlaIV, which recognizes the sequence
GGNNCC.
Frequency: Estimated from NlaIV restriction digest of PCR-
amplified 315 bp fragment containing all of exon 7.
Oligonucleotides used to prime amplification were 5' GGATGG-
AAGCTTACCGAAGAGGAC 3' and 5' CCTACCTTCG-
AATGGCTTCTCCTG 3' (from intron sequences flanking exon
7). In the presence of the Dl allele (ACT), the 315 bp fragment
remains uncut by NlaIV. In the presence of the D2 allele (A-
CC), fragments of 171 and 144 bp are generated. The figure
demonstrates homozygous D1, heterozygous and homozygous
D2 samples.
Estimated from 17 unrelated Caucasians:
D1 (ACT) = 0.76
D2 (ACC) = 0.24
Estimated from 5 unrelated American Blacks:
DI = 0.5
D2 = 0.5
Chromosomal Localization: The gene for human F.X has been
mapped to 13q34.
Other Comments: The polymorphism may have utility for RFLP
diagnosis in F.VII mutations, since F.VH and F.X are closely
linked on chromosome 13. This polymorphism differs from others
previously reported within the Factor X gene [2].
References: 1) Leytus. et al. (1986) Biochemistry 25,
5098-5102. 2) Hassan et al. (1988) Blood 71, 1353-1356.
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